Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib + R-CHOP in Newly Diagnosed DLBCL
NCT03225924Phase 2Terminated
- Sponsor
- LYSARC
- Start
- Jul 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of entospletinib in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Started Jul 2017; status: terminated.
02
Drugs
entospletinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03225924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225924.